CTNM
Contineum Therapeutics, Inc. Class A Common Stock
Biotechnology
Market Cap$443M
5Y Perf.-23.8%
Build Your Comparison
Side-by-side financial analysisCTNM
KYMR
IMVT
ARQT
Try popular comparisons:
Stock Comparison
CTNM vs KYMR vs IMVT vs ARQT
Revenue, margins, valuation, and 5-year total return — side by side.
KYMR
Kymera Therapeutics, Inc.
Biotechnology
Market Cap$6.77B
5Y Perf.+156.4%
IMVT
Immunovant, Inc.
Biotechnology
Market Cap$6.75B
5Y Perf.+22.5%
ARQT
Arcutis Biotherapeutics, Inc.
Biotechnology
Market Cap$3.08B
5Y Perf.+193.0%
CTNM vs KYMR vs IMVT vs ARQT — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot |  CTNM |  KYMR |  IMVT |  ARQT |
|---|---|---|---|---|
| Industry | Biotechnology | Biotechnology | Biotechnology | Biotechnology |
| Market Cap | $443M | $6.77B | $6.75B | $3.08B |
| Revenue (TTM) | $0.00 | $51M | $0.00 | $416M |
| Net Income (TTM) | $-58M | $-315M | $-506M | $-2M |
| Gross Margin | — | 33.2% | — | 90.9% |
| Operating Margin | — | -7.0% | — | 0.8% |
| Forward P/E | — | — | — | 122.5x |
| Total Debt | $8M | $82M | $72K | $6M |
| Cash & Equiv. | $76M | $357M | $902M | $43M |
CTNM vs KYMR vs IMVT vs ARQT — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
CTNM
KYMR
IMVT
ARQT
| Stock | Apr 24 | Jun 26 | Return |
|---|---|---|---|
| Contineum Therapeut… (CTNM) | 100 | 76.2 | -23.8% |
| Kymera Therapeutics… (KYMR) | 100 | 256.4 | +156.4% |
| Immunovant, Inc. (IMVT) | 100 | 122.5 | +22.5% |
| Arcutis Biotherapeu… (ARQT) | 100 | 293.0 | +193.0% |
Price return only. Dividends and distributions are not included.
Quick Verdict: CTNM vs KYMR vs IMVT vs ARQT
Each card shows where this stock fits in a portfolio — not just who wins on paper.
Bottom line: CTNM leads in 3 of 6 categories, making it the strongest pick for profitability and margin quality and capital preservation and lower volatility. Arcutis Biotherapeutics, Inc. is the stronger pick specifically for growth and revenue expansion and operational efficiency and capital deployment. As sector peers, any of these can serve as alternatives in the same allocation.
🥇CTNM emerged as the overall leader. Track its performance:
CTNM
Contineum Therapeutics, Inc. Class A Common Stock
The Income Pick
CTNM carries the broadest edge in this set and is the clearest fit for income & stability and sleep-well-at-night.
- beta 0.67
- Lower volatility, beta 0.67, Low D/E 3.2%, current ratio 27.50x
- Beta 0.67, current ratio 27.50x
- 3.0% margin vs KYMR's -6.1%
Best for: income & stability and sleep-well-at-night
KYMR
Kymera Therapeutics, Inc.
The Specific-Use Pick
KYMR plays a supporting role in this comparison — it may shine differently against other peers.
Best for: healthcare exposure
IMVT
Immunovant, Inc.
The Long-Run Compounder
IMVT is the clearest fit if your priority is long-term compounding.
- 230.5% 10Y total return vs KYMR's 149.4%
Best for: long-term compounding
ARQT
Arcutis Biotherapeutics, Inc.
The Growth Play
ARQT is the #2 pick in this set and the best alternative if growth exposure is your priority.
- Rev growth 91.3%, EPS growth 88.8%, 3Y rev CAGR 367.3%
- 91.3% revenue growth vs IMVT's -22.2%
- -0.6% ROA vs IMVT's -62.2%
Best for: growth exposure
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth |  ARQT | 91.3% revenue growth vs IMVT's -22.2% |
| Quality / Margins |  CTNM | 3.0% margin vs KYMR's -6.1% |
| Stability / Safety | CTNM | Beta 0.67 vs IMVT's 1.67 |
| Dividends | Tie | None of these 4 stocks pay a meaningful dividend |
| Momentum (1Y) | CTNM | +159.5% vs KYMR's +71.4% |
| Efficiency (ROA) | ARQT | -0.6% ROA vs IMVT's -62.2% |
CTNM vs KYMR vs IMVT vs ARQT — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
Segment breakdown not available.
Segment breakdown not available.
Segment breakdown not available.
FY 2023
CTNM vs KYMR vs IMVT vs ARQT — Financial Metrics
Side-by-side numbers across 4 stocks — who leads on profitability, valuation, growth, and risk.
BEST OVERALLARQTLAGGINGKYMR
Who Leads Where
ARQT leads in 3 of 6 categories
IMVT leads 1 • CTNM leads 0 • KYMR leads 0 • 1 tied
Explore the data ↓KYMRKymera Therapeutics, …
0leads
CTNMContineum Therapeutic…
0leads
IMVTImmunovant, Inc.
1leads
ARQTArcutis Biotherapeuti…
3leads
6 Total Categories
CATEGORYLEADERvs IMVTvs CTNMMETRICS WON
Income & Cash FlowRevenue, margins, and cash flow strength
ARQT6/6
Valuation MetricsMultiples, price ratios, and targets
ARQT2/3
Profitability & EfficiencyROE, ROIC, leverage, and quality scores
ARQT6/9
Total Returns1Y, 3Y, 5Y total returns with dividends
IMVT3/6
Risk & VolatilityBeta, volatility, and downside exposure
Tied
—
Analyst OutlookRatings, price targets, and dividends
—
—
Income & Cash Flow (Last 12 Months)
ARQT leads this category, winning 6 of 6 comparable metrics.
Income & Cash Flow (Last 12 Months)
ARQT and IMVT operate at a comparable scale, with $416M and $0 in trailing revenue. ARQT is the more profitable business, keeping -0.6% of every revenue dollar as net income compared to KYMR's -6.1%. On growth, ARQT holds the edge at +60.1% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | CTNMContineum Therape… |  KYMRKymera Therapeuti… | IMVTImmunovant, Inc. | ARQTArcutis Biotherap… |
|---|---|---|---|---|
| RevenueTrailing 12 months | $0 | $51M | $0 | $416M |
| EBITDAEarnings before interest/tax | -$67M | -$352M | -$532M | $6M |
| Net IncomeAfter-tax profit | -$58M | -$315M | -$506M | -$2M |
| Free Cash FlowCash after capex | -$58M | -$244M | -$407M | $27M |
| Gross MarginGross profit ÷ Revenue | — | +33.2% | — | +90.9% |
| Operating MarginEBIT ÷ Revenue | — | -7.0% | — | +0.8% |
| Net MarginNet income ÷ Revenue | — | -6.1% | — | -0.6% |
| FCF MarginFCF ÷ Revenue | — | -4.7% | — | +6.5% |
| Rev. Growth (YoY)Latest quarter vs prior year | — | +55.5% | — | +60.1% |
| EPS Growth (YoY)Latest quarter vs prior year | +37.1% | +13.4% | -14.1% | +55.0% |
ARQT leads this category, winning 6 of 6 comparable metrics.
Valuation Metrics
ARQT leads this category, winning 2 of 3 comparable metrics.
Valuation Metrics
| Metric | CTNMContineum Therape… | KYMRKymera Therapeuti… | IMVTImmunovant, Inc. | ARQTArcutis Biotherap… |
|---|---|---|---|---|
| Market CapShares × price | $443M | $6.8B | $6.8B | $3.1B |
| Enterprise ValueMkt cap + debt − cash | $376M | $6.5B | $5.8B | $3.0B |
| Trailing P/EPrice ÷ TTM EPS | -5.47x | -22.48x | -11.87x | -189.15x |
| Forward P/EPrice ÷ next-FY EPS est. | — | — | — | 122.45x |
| PEG RatioP/E ÷ EPS growth rate | — | — | — | — |
| EV / EBITDAEnterprise value multiple | — | — | — | — |
| Price / SalesMarket cap ÷ Revenue | — | 172.78x | — | 8.18x |
| Price / BookPrice ÷ Book value/share | 1.26x | 4.43x | 7.04x | 16.51x |
| Price / FCFMarket cap ÷ FCF | — | — | — | — |
ARQT leads this category, winning 2 of 3 comparable metrics.
Profitability & Efficiency
ARQT leads this category, winning 6 of 9 comparable metrics.
Profitability & Efficiency
ARQT delivers a -1.4% return on equity — every $100 of shareholder capital generates $-1 in annual profit, vs $-68 for IMVT. IMVT carries lower financial leverage with a 0.00x debt-to-equity ratio, signaling a more conservative balance sheet compared to KYMR's 0.05x. On the Piotroski fundamental quality scale (0–9), KYMR scores 4/9 vs IMVT's 2/9, reflecting mixed financial health.
| Metric | CTNMContineum Therape… | KYMRKymera Therapeuti… | IMVTImmunovant, Inc. | ARQTArcutis Biotherap… |
|---|---|---|---|---|
| ROE (TTM)Return on equity | -27.1% | -25.0% | -68.2% | -1.4% |
| ROA (TTM)Return on assets | -25.6% | -22.3% | -62.2% | -0.6% |
| ROICReturn on invested capital | -27.1% | -24.9% | — | -5.2% |
| ROCEReturn on capital employed | -29.0% | -27.2% | -68.3% | -4.3% |
| Piotroski ScoreFundamental quality 0–9 | 3 | 4 | 2 | 4 |
| Debt / EquityFinancial leverage | 0.03x | 0.05x | 0.00x | 0.03x |
| Net DebtTotal debt minus cash | -$67M | -$275M | -$902M | -$37M |
| Cash & Equiv.Liquid assets | $76M | $357M | $902M | $43M |
| Total DebtShort + long-term debt | $8M | $82M | $72,000 | $6M |
| Interest CoverageEBIT ÷ Interest expense | — | -2119.53x | — | 2.08x |
ARQT leads this category, winning 6 of 9 comparable metrics.
Total Returns (Dividends Reinvested)
IMVT leads this category, winning 3 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in IMVT five years ago would be worth $30,700 today (with dividends reinvested), compared to $7,701 for CTNM. Over the past 12 months, CTNM leads with a +159.5% total return vs KYMR's +71.4%. The 3-year compound annual growth rate (CAGR) favors KYMR at 48.9% vs CTNM's -8.3% — a key indicator of consistent wealth creation.
| Metric | CTNMContineum Therape… | KYMRKymera Therapeuti… | IMVTImmunovant, Inc. | ARQTArcutis Biotherap… |
|---|---|---|---|---|
| YTD ReturnYear-to-date | +4.1% | +14.0% | +26.9% | -15.2% |
| 1-Year ReturnPast 12 months | +159.5% | +71.4% | +103.6% | +79.1% |
| 3-Year ReturnCumulative with dividends | -23.0% | +230.0% | +51.6% | +140.8% |
| 5-Year ReturnCumulative with dividends | -23.0% | +64.1% | +207.0% | -13.3% |
| 10-Year ReturnCumulative with dividends | -23.0% | +149.4% | +230.5% | +12.8% |
| CAGR (3Y)Annualised 3-year return | -8.3% | +48.9% | +14.9% | +34.0% |
IMVT leads this category, winning 3 of 6 comparable metrics.
Risk & Volatility
Evenly matched — CTNM and IMVT each lead in 1 of 2 comparable metrics.
Risk & Volatility
CTNM is the less volatile stock with a 0.67 beta — it tends to amplify market swings less than IMVT's 1.67 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. IMVT currently trades 90.6% from its 52-week high vs CTNM's 72.6% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | CTNMContineum Therape… | KYMRKymera Therapeuti… | IMVTImmunovant, Inc. | ARQTArcutis Biotherap… |
|---|---|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 0.59x | 0.91x | 1.66x | 1.45x |
| 52-Week HighHighest price in past year | $16.33 | $103.00 | $36.27 | $31.77 |
| 52-Week LowLowest price in past year | $3.57 | $36.65 | $14.32 | $12.72 |
| % of 52W HighCurrent price vs 52-week peak | +72.6% | +80.5% | +90.6% | +77.4% |
| RSI (14)Momentum oscillator 0–100 | 32.8 | 47.7 | 51.9 | 59.9 |
| Avg Volume (50D)Average daily shares traded | 207K | 493K | 1.9M | 1.5M |
Evenly matched — CTNM and IMVT each lead in 1 of 2 comparable metrics.
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
Analyst consensus: CTNM as "Buy", KYMR as "Buy", IMVT as "Buy", ARQT as "Buy". Consensus price targets imply 38.3% upside for ARQT (target: $34) vs 32.8% for IMVT (target: $44).
| Metric | CTNMContineum Therape… | KYMRKymera Therapeuti… | IMVTImmunovant, Inc. | ARQTArcutis Biotherap… |
|---|---|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Buy | Buy | Buy | Buy |
| Price TargetConsensus 12-month target | $16.00 | $112.60 | $43.67 | $34.00 |
| # AnalystsCovering analysts | 3 | 26 | 23 | 12 |
| Dividend YieldAnnual dividend ÷ price | — | — | — | — |
| Dividend StreakConsecutive years of raises | — | — | — | — |
| Dividend / ShareAnnual DPS | — | — | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | 0.0% | 0.0% | 0.0% |
Insufficient data to determine a leader in this category.
Key Takeaway
ARQT leads in 3 of 6 categories (Income & Cash Flow, Valuation Metrics). IMVT leads in 1 (Total Returns). 1 tied.
Best OverallArcutis Biotherapeutics, In… (ARQT)Leads 3 of 6 categories
Loading custom metrics...
CTNM vs KYMR vs IMVT vs ARQT: Key Questions Answered
9 questions · data-driven answers · updated daily
01Is CTNM or KYMR or IMVT or ARQT a better buy right now?
For growth investors, Arcutis Biotherapeutics, Inc.
(ARQT) is the stronger pick with 91. 3% revenue growth year-over-year, versus -16. 7% for Kymera Therapeutics, Inc. (KYMR). Analysts rate Contineum Therapeutics, Inc. Class A Common Stock (CTNM) a "Buy" — based on 3 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which is the better long-term investment — CTNM or KYMR or IMVT or ARQT?
Over the past 5 years, Immunovant, Inc.
(IMVT) delivered a total return of +207. 0%, compared to -23. 0% for Contineum Therapeutics, Inc. Class A Common Stock (CTNM). Over 10 years, the gap is even starker: IMVT returned +237. 9% versus CTNM's -22. 9%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
03Which is safer — CTNM or KYMR or IMVT or ARQT?
By beta (market sensitivity over 5 years), Contineum Therapeutics, Inc.
Class A Common Stock (CTNM) is the lower-risk stock at 0. 59β versus Immunovant, Inc. 's 1. 66β — meaning IMVT is approximately 180% more volatile than CTNM relative to the S&P 500. On balance sheet safety, Immunovant, Inc. (IMVT) carries a lower debt/equity ratio of 0% versus 5% for Kymera Therapeutics, Inc. — giving it more financial flexibility in a downturn.
04Which is growing faster — CTNM or KYMR or IMVT or ARQT?
By revenue growth (latest reported year), Arcutis Biotherapeutics, Inc.
(ARQT) is pulling ahead at 91. 3% versus -16. 7% for Kymera Therapeutics, Inc. (KYMR). On earnings-per-share growth, the picture is similar: Arcutis Biotherapeutics, Inc. grew EPS 88. 8% year-over-year, compared to -33. 1% for Contineum Therapeutics, Inc. Class A Common Stock. Over a 3-year CAGR, ARQT leads at 367. 3% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
05Which has better profit margins — CTNM or KYMR or IMVT or ARQT?
Contineum Therapeutics, Inc.
Class A Common Stock (CTNM) is the more profitable company, earning 0. 0% net margin versus -794. 4% for Kymera Therapeutics, Inc. — meaning it keeps 0. 0% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: CTNM leads at 0. 0% versus -891. 3% for KYMR. At the gross margin level — before operating expenses — KYMR leads at 100. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
06Is CTNM or KYMR or IMVT or ARQT more undervalued right now?
Analyst consensus price targets imply the most upside for ARQT: 38.
3% to $34. 00.
07Which pays a better dividend — CTNM or KYMR or IMVT or ARQT?
None of the stocks in this comparison currently pay a material dividend.
All are effectively zero-yield and should be held for capital appreciation rather than income.
08Is CTNM or KYMR or IMVT or ARQT better for a retirement portfolio?
For long-horizon retirement investors, Contineum Therapeutics, Inc.
Class A Common Stock (CTNM) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 59)). Immunovant, Inc. (IMVT) carries a higher beta of 1. 66 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (CTNM: -22. 9%, IMVT: +237. 9%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
09What are the main differences between CTNM and KYMR and IMVT and ARQT?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
In terms of investment character: CTNM is a small-cap quality compounder stock; KYMR is a small-cap quality compounder stock; IMVT is a small-cap quality compounder stock; ARQT is a small-cap high-growth stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.